跳至主要内容
临床试验/NL-OMON36798
NL-OMON36798撤回3 期

An Open-label, Multi-centre, Un-controlled Trial to Assess Efficacy and Safety of NNC-0156-0000-0009 during Surgical Procedures in Patients with Haemophilia B - Paradigm3

ovo Nordisk0 个研究点目标入组 2 人开始时间: 待定最近更新:
适应症

试验速览

阶段
3 期
状态
撤回
发起方
入组人数
2

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 99(—)

入选标准

  • Male patients, aged 13-70 years, with moderately severe or severe congenital haemophilia B with a FIX activity <=2% according to medical records
  • NB: In The Netherlands only patients aged 18-70 years will be included
  • History of at least 150 exposure days to other FIX products
  • Scheduled major surgery

排除标准

  • Known history of FIX inhibitors based on existing medical records, laboratory report reviews and patient and LAR interviews
  • Current FIX inhibitors >=0.6 BU (central laboratory)
  • Previous arterial thrombotic events (e.g. myocardial infarction and intracranial thrombosis) or previous deep venous thrombosis or pulmonary embolism (as defined by available medical records)
  • ALT >3 times the upper limit of normal reference ranges at screening (central laboratory)
  • Immune modulating or chemotherapeutic medication

研究者

发起方
ovo Nordisk

相似试验